| # | Country | Total Patents | |
|---|---|---|---|
| #1 | United States | 12 | |
| #2 | Australia | 6 | |
| #3 | EPO (European Patent Office) | 6 | |
| #4 | WIPO (World Intellectual Property Organization) | 5 | |
| #5 | Canada | 4 | |
| #6 | China | 4 | |
| #7 | Israel | 4 | |
| #8 | Republic of Korea | 4 | |
| #9 | Brazil | 3 | |
| #10 | Singapore | 3 | |
| #11 | Japan | 2 | |
| #12 | Mexico | 2 | |
| #13 | Taiwan | 1 | |
| #14 | South Africa | 1 |
| # | Industry | |
|---|---|---|
| #1 | Biotechnology | |
| #2 | Pharmaceuticals | |
| #3 | Measurement | |
| #4 | Medical technology | |
| #5 | Machines |
| # | Technology | |
|---|---|---|
| #1 | Analysing materials | |
| #2 | Peptides | |
| #3 | Therapeutic chemical compounds | |
| #4 | Microorganisms | |
| #5 | Medical preparations | |
| #6 | Measuring microorganism processes | |
| #7 | Object sterilising | |
| #8 | Unspecified technologies |
| # | Name | Total Patents |
|---|---|---|
| #1 | Lundgren Åkerlund Evy | 20 |
| #2 | Chmielarska Masoumi Katarzyna | 19 |
| #3 | Talts Jan | 15 |
| #4 | Lundgren Akerlund Evy | 13 |
| #5 | Lundgren-Akerlund Evy | 9 |
| #6 | Uvebrant Christina | 8 |
| #7 | Gisler Ramiro | 7 |
| #8 | Evy Lundgren Åkerlund | 5 |
| #9 | Katarzyna Chmielarska Masoumi | 3 |
| #10 | Lundgren-Åkerlund Evy | 3 |
| Publication | Filing date | Title |
|---|---|---|
| WO2020212416A1 | Integrin alpha10 and aggressive cancer forms | |
| CA3067109A1 | Quality assurance of chondrocytes | |
| WO2018138322A1 | Prevention and treatment of bone and cartilage damage or disease | |
| BR112019003147A2 | use of a marker, methods for identifying a mammalian neural stem cell and / or a mammalian neural progenitor cell, for isolating a mammalian neural stem cell and / or a mammalian neural progenitor cell, to determine whether a compound of The test modulates a mammalian neural stem cell and / or mammalian neural progenitor cell differentiation in vitro, to produce an isolated mammalian cell population in vitro, to treat disease or damage and / or to prevent and protect against system damage. nervous system in an individual, to treat a mental or behavioral disorder in an individual and to determine the characteristics of a damaged or diseased snc area in a patient, in vitro cell culture, suspension culture, mammalian neural stem cell marker and / or for mammalian neural progenitor cells, and, composition. | |
| AU2016220535A1 | Detection and treatment of malignant tumours in the CNS | |
| AU2003239016A1 | Marker for stem cells and its use |